• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

    6/20/25 7:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.
    • Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.

    CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes to eat better and feel healthier, with participants reporting improved diet quality and health status.

    This study is one of the few randomized controlled clinical trials examining the impact of food is medicine programs. Conducted by the Public Health Institute Center for Wellness and Nutrition (PHI CWN), this clinical trial assessed the impact of Abbott's Healthy Food Rx in a highly food insecure, low-income, community-based setting of 364 people living with diabetes over a six-month period. The Healthy Food Rx program provides home-delivered, meal-based healthy food boxes accompanied by nutrition education to help address diabetes.

    Key study results include:

    • Improved diet quality: Healthy Food Rx participants reported significantly increased vegetable consumption compared to the control group (0.37 vs. 0.03 increased servings per day; p = 0.007), and increased fruit consumption compared to control group (0.3 vs. 0.2 increased servings per day, p = 0.232).
    • Improved health status: Healthy Food Rx participants reported significantly greater improvements in self-reported physical health status over six months (from 38% to 63%, p < 0.001), compared to the control group (from 47% to 50%, p=0.453; between group p<0.001).
    • Lowered A1C levels in both groups: A1C levels significantly improved for both Healthy Food Rx participants and the control group. A1C is a test that reflects average glucose levels for the past three months; levels decreased by 0.7% and 1.2%, in the intervention group and control group, respectively. Both values exceeded the widely accepted 0.5% benchmark that is considered a clinically significant change and is associated with improved health outcomes in people with diabetes.
    • Participants were strongly satisfied with Healthy Food Rx, and shared with family and friends. Participants in Abbott's Healthy Food Rx reported strong satisfaction – 98% were satisfied with the program and 97% used all or most of the food. Two-thirds of participants (67%) shared the food with two or more people, and 99% were likely to recommend the program to others.

    "Living with diabetes in an economically underserved community can present numerous challenges, from limited access to affordable, healthy foods to a lack of appropriate health services," said Erika Takada, Executive Director, Public Health Institute Center for Wellness and Nutrition. "Even with a program that reaches participants just twice a month, we are seeing benefits in people with diabetes eating better foods and feeling healthier. This underscores the foundational role that good nutrition can play in helping to address the impact of diabetes and other chronic diseases on our families and communities."

    Launched in 2021, Abbott's Healthy Food Rx is one of the largest community-focused food is medicine programs in the country, reaching more than 1,700 participants to date. These clinical trial findings build on results of an earlier 12-month study that showed clinically important benefits among Healthy Food Rx participants living with diabetes.

    "Programs like Abbott's Healthy Food Rx are critically important in communities like Stockton where diabetes incidence and risk are significantly higher," said Kwabena O. Adubofour, MD, FACP, Internal Medicine Specialist and a Board Certified Diabetologist at Community Medical Centers (CMC) in Stockton. "From results like A1C reduction to even personal well-being, participants from the CMC clinic benefited greatly from access to healthy foods and nutrition resources. It will be important to see how these benefits translate into long-term improvements in diabetes outcomes so people can lead healthier, fuller lives."

    "We're pleased that results from Abbott's Healthy Food Rx can contribute to a better understanding of the impacts that programs like this can have for people living with diabetes," said Melissa Brotz, president of Abbott Fund and senior vice president of Global Marketing and External Affairs at Abbott. "By integrating healthy food and nutrition education as part of a broader effort to remove barriers to care, we're helping people to feel more in control and take an active role in managing their health."

    About the Clinical Trial

    A delayed intervention randomized clinical trial design was used. Participants were recruited by health educators and randomized into two groups: the intervention group received home-delivered, meal-based food boxes once every other week for six months with nutrition education in the form of recipes, cooking videos and text messages; the control group received the intervention after the six-month study period. All participants received usual care, including potential medication prescriptions and optional diabetes education and social needs referrals.

    Participants were administered surveys at enrollment and after six months, with hemoglobin A1C assessed as the primary outcome, and secondary outcomes including fruit and vegetable intake, food security and health status. Study results can be found here.

    About Abbott's Healthy Food Rx

    Abbott's Healthy Food Rx program is part of the company's Future Well™ Communities initiative, a multi-year effort to advance health access by removing the barriers that prevent people with diabetes from living healthy lives.

    Abbott partnered with PHI CWN to design and implement Healthy Food Rx with Stockton-based organizations, with funding support from Abbott's foundation, Abbott Fund. CMC, a local federally qualified health center in Stockton, identified potential Healthy Food Rx participants. Program participants received food boxes from the Emergency Food Bank Stockton/San Joaquin (EFB), delivered directly to their home every other week for six months. The boxes included ingredients for a family-sized healthy meal with lean protein, vegetables and fruits, as well as pantry staples such as beans, rice and nuts. The box also contained a recipe card and link to an optional online cooking class with EFB, which provided additional guidance and diabetes education.

    About the Public Health Institute and the Center for Wellness and Nutrition

    The Public Health Institute, an independent nonprofit organization, advances wellbeing and health equity with communities around the world. PHI develops research, leadership and partnerships to build strong public health policy, programs, systems and practices. For more information, visit phi.org. The Center for Wellness and Nutrition (CWN, centerforwellnessandnutrition.org), a program of the Public Health Institute, is a national leader in developing campaigns, programs and partnerships to promote wellness and equitable practices in the most vulnerable communities in California and across the country.

    About Abbott and Abbott Fund

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Abbott Fund is a philanthropic foundation established by Abbott in 1951. Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide. For more information on Abbott Fund, visit www.abbottfund.org.

    Cision View original content:https://www.prnewswire.com/news-releases/new-research-on-abbotts-healthy-food-rx-program-shows-food-is-medicine-approach-helps-people-living-with-diabetes-eat-better-and-feel-healthier-302487489.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/5/26 6:46:46 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

    Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to significantly reduce AFib episodes for complex cases2ABBOTT PARK, Ill., Feb. 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minim

    2/6/26 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

    Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpointABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025. Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-re

    1/22/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

    Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging casesIt can deliver both radiofrequency energy and pulsed field ablation (PFA) energy during procedures to target and treat an irregular heart rhythmThe availability of TactiFlex Duo in Europe adds a dual-energy, focal ablation catheter to Abbott's growing PFA portfolio, following the company's Volt PFA System approvals in the U.S. and Europe last yearABBOTT PARK, Ill., Jan. 20, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has received CE Mark in Europe for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients

    1/20/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    1/22/26 7:35:32 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    12/12/25 4:10:48 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    11/21/25 4:06:09 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

    Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpointABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025. Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-re

    1/22/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities